EP0771201A1 - Methods of inhibiting primary endometrial hyperplasia - Google Patents
Methods of inhibiting primary endometrial hyperplasiaInfo
- Publication number
- EP0771201A1 EP0771201A1 EP95930875A EP95930875A EP0771201A1 EP 0771201 A1 EP0771201 A1 EP 0771201A1 EP 95930875 A EP95930875 A EP 95930875A EP 95930875 A EP95930875 A EP 95930875A EP 0771201 A1 EP0771201 A1 EP 0771201A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- endometrial
- compound
- estrogen
- formula
- hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the uterine lining (endometrium) is composed of tissue, blood vessels, and glands that grow when stimulated by the hormone estrogen.
- estrogen In women with normal menstrual cycles, hormonal fluctuations trigger the growth and shedding of the endometrium each month. If conception occurs, the endometrium nourishes the developing embryo. With continuously elevated estrogen levels, the endometrium remains in its growth phase at all time, leading to an overabundance of endometrial tissue or endo etrial hyperplasia. Overgrowth of the endometrium is often a benign condition, but it can also be a precursor of endometrial cancer. Because of this risk, doctors urge women avoid long-term estrogen therapy, which can cause endometrial overgrowth, and to seek prompt treatment for conditions that cause excessive estrogen production.
- endometrial hyperplasia Most cases of endometrial carcinoma are associated with a precursor lesion termed "endometrial hyperplasia.”
- the classification of endometrial hyperplasia is based on the presence or absence of cytologic atypia, the presence of dysplasia, and the degree of complexity of the architectural pattern. Cytologic atypia is the most predictive criterion for the likelihood of progression to carcinoma. In simple or cystic hyperplasia with cytologic atypia present there is about an 8% chance of progression to cancer. With complex or adenomatous hyperplasia with cytologic atypia present, there is 29% chance. When no cytologic atypia is present, the progression rate is 1% for simple and 3% for complex hyperplasia.
- Gynecologists diagnose the disorder by examining endometrial tissue taken either as a biopsy or in a procedure called a D&C (dilation and curettage) , which involves dilating the cervix and using a sharp, curved instrument to scrape out the entire endometrium. Neither of these procedures is performed routinely. Instead, doctors recommend them for people who have symptoms of endometrial overgrowth or who are at risk of developing it, including post-menopausal women on estrogen therapy and women who are obese or who have fertility problems.
- D&C diilation and curettage
- R 1 and R 3 are independently hydrogen
- R 2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof
- the current invention concerns the discovery that a select group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes) , those of formula I, are useful for inhibiting primary endometrial hyperplasia.
- the therapeutic and prophylactic treatments provided by this invention are practiced by administering to a human in need thereof a dose of a compound of formula I or a pharmaceutically acceptable salt or. solvate thereof, that is effective to inhibit primary endometrial hyperplasia or its symptoms.
- inhibitor includes its generally accepted meaning which includes prohibiting, preventing, restraining, and slowing, stopping or reversing progression, severity or a resultant symptom.
- the present method includes both medical therapeutic and/or prophylactic administration, as appropriate.
- Raloxifene is a preferred compound of this invention and it is the hydrochloride salt of a compound of formula 1 wherein R 1 and R 3 are hydrogen and R 2 is 1- piperidinyl.
- At least one compound of formula I is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes.
- the compounds can be administered transdermally, and may be formulated as sustained release dosage forms and the like.
- the compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent Nos. 4,133,814,
- the compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention.
- Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosph ⁇ ric and the like.
- Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ⁇ -hydroxybutyrate, butyne-1, 4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride ' , cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydr
- the pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid.
- the reactants are generally combined in a mutual solvent such as diethyl ether or benzene.
- the salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
- Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines.
- Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.
- the pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
- compositions can be prepared by procedures known in the art.
- the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like.
- excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid
- the compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like.
- the formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time.
- the coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
- a compound of formula I required to inhibit primary endometrial hyperplasia or its symptoms, according to this invention, will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered to a subject in need thereof from once to about three times each day, or more often as needed, and for a time to effectively treat or prevent the disease or its symptoms.
- Hard gelatin capsules are prepared using the following :
- the ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
- Silicone fluid 350 centistokes 1.7 Formulation 4 Raloxifene capsule
- Silicone fluid 350 centistokes 3.0
- a tablet formulation is prepared using the ingredients below:
- the components are blended and compressed to form tablets.
- tablets each containing 0.1 - 1000 mg of Active ingredient are made up as follows: Formulation 7 : Tablets
- the Active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
- the solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve.
- the granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve.
- the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets .
- Tissue from human or animal endometrial lesions are harvested and maintained in vitro as primary cultures. Surgical specimens are pushed through a sterile mesh or sieve or alternately teased or digested apart from surrounding tissue to produce a single cell suspension.
- cultures are propagated from tissue explants. Cells are maintained in growth media containing serum and antibiotics.
- Rates of growth in the presence and absence of estrogen is determined. In vitro cultures are assessed for their proliferative response following treatment with estrogen, progestins, and compounds of Formula I. Levels of steroid hormone receptors are assessed to determine whether important cell characteristics are maintained in vitro. Tissue from 1-10 patients are utilized. In absence of a proliferative response, estrogen and anti-estrogen effects are assessed by monitoring transcriptional activation of estrogen regulated genes.
- Estrogen receptor containing cells such as the Ishikawa line
- Responsiveness is assessed by monitoring transcription of known estrogen/anti-estrogen regulated genes such as progesterone receptor, P ⁇ 2 and others.
- ASSAY 2 Induced Animal Models - Uterine hyperplasia and carcinoma is induced by injections of estrogenic substances such as 17- ⁇ -estradiol or DES during neonatal development. The presence of hyperplasia or carcinoma in the adult animal is confirmed by biopsy or affected animals and/or sacrifice and biopsy of syngeneic animals identically treated. After evaluation of the lesions, affected animals are treated with estrogen, compounds of formula I, or progestins for 1-8 weeks. After treatment, lesions of surviving animals are examined for progression, regression or stasis.
- estrogenic substances such as 17- ⁇ -estradiol or DES during neonatal development.
- the presence of hyperplasia or carcinoma in the adult animal is confirmed by biopsy or affected animals and/or sacrifice and biopsy of syngeneic animals identically treated. After evaluation of the lesions, affected animals are treated with estrogen, compounds of formula I, or progestins for 1-8 weeks. After treatment, lesions of surviving animals are examined for progression, regression or stasis.
- Xenograft models Implantation of endometrial lesions from humans or other animals or transformed cultured cells into immunodeficient rodents. Tissue from endometrial lesions is implanted into the peritoneum or under the skin of sexually mature, castrated female immunocompromised rodents. Exogenous estrogen is supplied to induce growth of the explanted tissue. In some cases the harvested endometrial cells are cultured in vitro prior to implantation. Treatment consisting of estrogens, a compound of formula I, or vehicle will be supplied by gastric lavage on a daily basis for 3-16 weeks. Following treatment, implants are assessed for growth or regression. At the time of sacrifice, the uteri are harvested to assess the status of the intact endometrium.
- the women suffer from primary endometrial hyperplasia, but otherwise are in good general health.
- the study has a placebo control group, i.e., the women are divided into two groups, one of which receives a compound of formula 1 as the active agent and the other receives a placebo. Women in the test group receive between 50-200 mg of the drug per day by the oral route. They continue this therapy for 3-12 months. Accurate records are kept as to the number and severity of the symptoms in both groups and at the end of the study these results are compared. The results are compared both between members of each group and also the results for each patient are compared to the symptoms reported by each patient before the study began.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29412194A | 1994-08-22 | 1994-08-22 | |
US294121 | 1994-08-22 | ||
PCT/US1995/010619 WO1996005832A1 (en) | 1994-08-22 | 1995-08-21 | Methods of inhibiting primary endometrial hyperplasia |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0771201A1 true EP0771201A1 (en) | 1997-05-07 |
EP0771201A4 EP0771201A4 (en) | 1997-09-10 |
EP0771201B1 EP0771201B1 (en) | 2001-04-18 |
Family
ID=23131973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95930875A Expired - Lifetime EP0771201B1 (en) | 1994-08-22 | 1995-08-21 | Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting primary endometrial hyperplasia |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0771201B1 (en) |
JP (1) | JPH10504579A (en) |
KR (1) | KR970705388A (en) |
AT (1) | ATE200623T1 (en) |
AU (1) | AU706953B2 (en) |
CA (1) | CA2198120A1 (en) |
CZ (1) | CZ52297A3 (en) |
DE (1) | DE69520741T2 (en) |
DK (1) | DK0771201T3 (en) |
ES (1) | ES2155895T3 (en) |
FI (1) | FI970716A (en) |
GR (1) | GR3036225T3 (en) |
HU (1) | HUT76854A (en) |
IL (1) | IL115018A0 (en) |
MX (1) | MX9701359A (en) |
MY (1) | MY131931A (en) |
NO (1) | NO970787D0 (en) |
PT (1) | PT771201E (en) |
WO (1) | WO1996005832A1 (en) |
ZA (1) | ZA956988B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ292017A (en) * | 1994-08-22 | 2000-07-28 | Lilly Co Eli | Use of raloxifene to treat endometrial cancer |
US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0652004A1 (en) * | 1993-10-15 | 1995-05-10 | Eli Lilly And Company | Methods for treating resistant neoplasms |
EP0652005A1 (en) * | 1993-10-15 | 1995-05-10 | Eli Lilly And Company | Methods for inhibiting endometriosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3157882B2 (en) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
-
1995
- 1995-08-21 AU AU34098/95A patent/AU706953B2/en not_active Ceased
- 1995-08-21 ZA ZA9506988A patent/ZA956988B/en unknown
- 1995-08-21 DE DE69520741T patent/DE69520741T2/en not_active Expired - Fee Related
- 1995-08-21 WO PCT/US1995/010619 patent/WO1996005832A1/en active IP Right Grant
- 1995-08-21 EP EP95930875A patent/EP0771201B1/en not_active Expired - Lifetime
- 1995-08-21 MX MX9701359A patent/MX9701359A/en unknown
- 1995-08-21 CA CA002198120A patent/CA2198120A1/en not_active Abandoned
- 1995-08-21 AT AT95930875T patent/ATE200623T1/en not_active IP Right Cessation
- 1995-08-21 ES ES95930875T patent/ES2155895T3/en not_active Expired - Lifetime
- 1995-08-21 IL IL11501895A patent/IL115018A0/en unknown
- 1995-08-21 DK DK95930875T patent/DK0771201T3/en active
- 1995-08-21 CZ CZ97522A patent/CZ52297A3/en unknown
- 1995-08-21 HU HU9701500A patent/HUT76854A/en unknown
- 1995-08-21 JP JP8508252A patent/JPH10504579A/en active Pending
- 1995-08-21 PT PT95930875T patent/PT771201E/en unknown
- 1995-08-21 MY MYPI95002468A patent/MY131931A/en unknown
- 1995-08-21 KR KR1019970701099A patent/KR970705388A/en not_active Application Discontinuation
-
1997
- 1997-02-20 NO NO970787A patent/NO970787D0/en unknown
- 1997-02-20 FI FI970716A patent/FI970716A/en unknown
-
2001
- 2001-07-13 GR GR20010401076T patent/GR3036225T3/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0652004A1 (en) * | 1993-10-15 | 1995-05-10 | Eli Lilly And Company | Methods for treating resistant neoplasms |
EP0652005A1 (en) * | 1993-10-15 | 1995-05-10 | Eli Lilly And Company | Methods for inhibiting endometriosis |
Non-Patent Citations (6)
Title |
---|
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 761, 12 June 1995, USA, pages 355-360, XP000654717 FUCHS-YOUNG, R., ET AL.: "RALOXIFENE IS A TISSUE-SELECTIVE AGONIST/ANTAGONIST THAT FUNCTIONS THROUGH THE ESTROGEN RECEPTOR" * |
BREAST CANCER RES. TREAT., vol. 2, no. 3, 1982, NETHERLANDS, page 279 XP002034737 JONES, D., ET AL.: "LY156758:A UNIQUE ANTIESTROGEN DISPLAYING HIGH AFFINITY FOR ESTROGEN RECEPTORS, NEGLIGIBLE ESTROGENIC ACTIVITY AND NEAR-TOTAL ESTROGEN ANTAGONISM IN VIVO." * |
BREAST CANCER RES. TREAT., vol. 36, no. 3, 1995, NETHERLANDS, pages 267-285, XP000654844 V.CRAIG JORDAN: "STUDIES ON THE ESTROGEN RECPTOR IN BREAST CANCER-20 YEARS AS A TARGET FOR THE TREATMENT AND PREVENTION OF CANCER" * |
CANCER RES., vol. 50, no. 11, June 1990, USA, pages 3189-3192, XP000654576 GOTTARDIS M.,M., ET AL.: "EFFECT OF STEROIDAL AND NONSTEROIDAL ANTIESTROGENS ON THE GROWTH OF A TAMOXIFENE-STIMULATED HUMAN ENDOMETRIAL CARCINOMA (ENCA101) IN ATHYMIC MICE" * |
DRUG DEVELOPMENT RESEARCH , vol. 36, no. 1, 1995, USA, pages 43-45, XP000654665 SWISHER K.D., ET AL.: "EFFECT OF THE SELECTIVE ESTROGEN RECEPTOR MODULATOR RALOXIFENE ON EXPLANTED UTERINE GROWTH IN RATS" * |
See also references of WO9605832A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO970787L (en) | 1997-02-20 |
MY131931A (en) | 2007-09-28 |
CA2198120A1 (en) | 1996-02-29 |
FI970716A0 (en) | 1997-02-20 |
EP0771201B1 (en) | 2001-04-18 |
IL115018A0 (en) | 1995-12-08 |
NO970787D0 (en) | 1997-02-20 |
FI970716A (en) | 1997-02-20 |
ZA956988B (en) | 1997-02-21 |
ATE200623T1 (en) | 2001-05-15 |
HUT76854A (en) | 1997-12-29 |
WO1996005832A1 (en) | 1996-02-29 |
CZ52297A3 (en) | 1997-08-13 |
EP0771201A4 (en) | 1997-09-10 |
DE69520741D1 (en) | 2001-05-23 |
DE69520741T2 (en) | 2001-10-11 |
AU706953B2 (en) | 1999-07-01 |
KR970705388A (en) | 1997-10-09 |
DK0771201T3 (en) | 2001-05-07 |
PT771201E (en) | 2001-07-31 |
JPH10504579A (en) | 1998-05-06 |
ES2155895T3 (en) | 2001-06-01 |
MX9701359A (en) | 1997-05-31 |
GR3036225T3 (en) | 2001-10-31 |
AU3409895A (en) | 1996-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5693656A (en) | Methods for inhibiting endometriosis | |
US5496828A (en) | Methods of inhibiting ulcerative mucositis | |
US5446053A (en) | Methods of inhibiting dysfunctional uterine bleeding | |
AU701701B2 (en) | Methods of inhibiting breast disorders | |
EP0771201B1 (en) | Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting primary endometrial hyperplasia | |
AU688112B2 (en) | Methods of inhibiting endometrial cancer | |
AU732473B2 (en) | Methods of increasing sphincter competence | |
US5502074A (en) | Benzothiophenes for bone healing and fracture repair | |
US5843964A (en) | Methods of inhibiting endometrial mitoses | |
JPH10504577A (en) | How to control nerve damage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970218 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19970721 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19971212 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/4535 A, 7A 61K 31/4025 B, 7A 61K 31/381 B |
|
RTI1 | Title (correction) |
Free format text: USE OF 2-PHENYL-3-AROYLBENZOTHIOPHENES FOR THE PREPARATION OF A MEDICAMENT FOR INHIBITING PRIMARY ENDOMETRIAL HYPERPLASIA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 200623 Country of ref document: AT Date of ref document: 20010515 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20010515 Year of fee payment: 7 |
|
REF | Corresponds to: |
Ref document number: 69520741 Country of ref document: DE Date of ref document: 20010523 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20010529 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2155895 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20010719 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20010725 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20010419 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20010816 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20010817 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20010820 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20010829 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20010830 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20010831 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20020626 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020805 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020821 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020821 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020821 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020822 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20020828 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20020830 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 |
|
BERE | Be: lapsed |
Owner name: *ELI LILLY AND CY Effective date: 20020831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030305 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20030301 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030821 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040302 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040430 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20030822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050821 |